LRRK2 and Parkinson disease: Evidence of an inverse relationship between LRRK2 and GCase activity came from a recent study showing that DA neurons derived from iPSCs procured from PD patients with the LRRK2 risk variant G2019S had reduced GCase activity, which was reversible by treatment with the LRRK2 inhibitor MLi-2 [106].